Key result
18F-FDG PET/CT identifies MRI-negative cardiac sarcoidosis, guiding early therapy that improves LVEF to 52%.
18F-FDG PET/CT is critical for diagnosing active cardiac sarcoidosis when CMR is negative, and early synergistic use of methotrexate and GDMT can reverse severe corticosteroid-refractory ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
Potential EF recovery in refractory cardiac sarcoidosis with methotrexate plus GDMT; leaves open need for prospective trials.
Background: Cardiac involvement significantly impacts the prognosis of sarcoidosis. While conduction abnormalities represent the classic presentation, inaugural acute heart failure with severe left ventricular dysfunction is a less common and diagnostically challenging phenotype that can closely mimic idiopathic dilated cardiomyopathy. Furthermore, diagnosing cardiac sarcoidosis (CS) can be complex when initial advanced imaging yields false-negative results. Case Presentation: A 43-year-old female with a history of cutaneous sarcoidosis, maintained on chronic oral corticosteroids, presented with rapidly progressive heart failure (New York Heart Association class III). Transthoracic echocardiography revealed severe left ventricular systolic dysfunction with an ejection fraction of 26%. Her clinical course was notably complicated by an episode of paroxysmal atrial fibrillation and a subsequent transient ischemic attack (TIA). Cardiac magnetic resonance (CMR) imaging was non-contributory, showing no evidence of edema or late gadolinium enhancement. However, due to high clinical suspicion, an 18F-FDG PET/CT was performed, revealing intense, multifocal myocardial uptake indicative of active granulomatous inflammation. Recognising the corticosteroid-refractory nature of her flare-up, she was treated with intravenous corticosteroid pulses, followed by the early introduction of methotrexate as a steroid-sparing agent, optimised guideline-directed medical therapy (GDMT) for heart failure, and therapeutic anticoagulation with apixaban. At one year, the patient was completely asymptomatic with a full normalisation of her ejection fraction to 52%. Conclusion: This case highlights that a normal CMR does not exclude active cardiac sarcoidosis, especially in the early inflammatory stages, reinforcing the critical diagnostic value of 18F-FDG PET/CT. Additionally, it demonstrates that severe, corticosteroid-refractory ventricular dysfunction can achieve complete functional reversibility through the early and synergistic use of methotrexate and GDMT.
No takes yet. Share an insight, caveat, or question.
Nafidi et al. (2026) studied this question. 18F-FDG PET/CT identified active cardiac sarcoidosis despite a negative MRI, enabling early methotrexate and medical therapy to improve left ventricular ejection fraction from 26% to 52%.
Synapse has enriched 10 related papers. Consider them for comparative context: